An organic compound represented by the formula [1]:

##STR00001##

R.sub.1 to R.sub.19 are independently selected from the group consisting of a hydrogen atom, a deuterium atom, a halogen atom, and a substituent, and R.sub.9 and R.sub.19 are optionally bonded together. When R.sub.9 and R.sub.19 are bonded together, the bonding is selected from the group consisting of direct bonding, bonding via an oxygen atom or a sulfur atom, and bonding via CR.sub.20R.sub.21. R.sub.20 and R.sub.21 independently have the same meaning as R.sub.1 to R.sub.19. X.sub.1 and X.sub.2 independently denote an oxygen atom, a sulfur atom, CR.sub.20R.sub.21, or a single bond. Ar denotes an aromatic hydrocarbon group or a heterocyclic group, n denotes an integer in the range of 0 to 2, and m denotes an integer in the range of 1 to 4. When n is 0, any one of R.sub.1 to R.sub.8 is directly bonded to any one of R.sub.9 to R.sub.19.

An organic compound represented by the formula [1]:

##STR00001##

R.sub.1 to R.sub.19 are independently selected from the group consisting of a hydrogen atom, a deuterium atom, a halogen atom, and a substituent, and R.sub.9 and R.sub.19 are optionally bonded together. When R.sub.9 and R.sub.19 are bonded together, the bonding is selected from the group consisting of direct bonding, bonding via an oxygen atom or a sulfur atom, and bonding via CR.sub.20R.sub.21. R.sub.20 and R.sub.21 independently have the same meaning as R.sub.1 to R.sub.19. X.sub.1 and X.sub.2 independently denote an oxygen atom, a sulfur atom, CR.sub.20R.sub.21, or a single bond. Ar denotes an aromatic hydrocarbon group or a heterocyclic group, n denotes an integer in the range of 0 to 2, and m denotes an integer in the range of 1 to 4. When n is 0, any one of R.sub.1 to R.sub.8 is directly bonded to any one of R.sub.9 to R.sub.19.

IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a K.sub.d of less than 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposed are also disclosed.

IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a K.sub.d of less than 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposed are also disclosed.

Provided is a novel compound capable of improving the luminous efficiency and stability of a device, an organic electronic element using the same, and an electronic device thereof.

The present disclosure provides compounds of Formulae (I-A), (II′), (III-A), (IV′), and (V-A), wherein the compounds are derived from or based on yohimbine. The provided compounds may be useful in treating or preventing a disease (e.g., proliferative disease, cancers, inflammatory diseases, autoimmune diseases, and infectious diseases) in a subject in need thereof. The present disclosure provides methods of preparing compounds of Formulae (I-A), (II′), (III-A), (IV′), and (V-A). Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein. ##STR00001##

The present disclosure provides compounds of Formulae (I-A), (II′), (III-A), (IV′), and (V-A), wherein the compounds are derived from or based on yohimbine. The provided compounds may be useful in treating or preventing a disease (e.g., proliferative disease, cancers, inflammatory diseases, autoimmune diseases, and infectious diseases) in a subject in need thereof. The present disclosure provides methods of preparing compounds of Formulae (I-A), (II′), (III-A), (IV′), and (V-A). Also provided are pharmaceutical compositions, kits, methods, and uses that include or involve a compound described herein. ##STR00001##

The present invention concerns compounds of formula I or pharmaceutically acceptable salts thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.

##STR00001##

The present invention concerns compounds of formula I or pharmaceutically acceptable salts thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier.

##STR00001##

The present invention relates to Tetracyclic Heterocycle Compounds of Formula ##STR00001##
and pharmaceutically acceptable salts or prodrug thereof, wherein A, X, R.sup.1, R.sup.2, R.sup.3 and Ware as defined herein. The present invention also relates to compositions comprising at least one Tetracyclic Heterocycle Compound, and methods of using the Tetracyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.